Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.93

-0.1%

2:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lance Bredvold	2/1/2022 1:26:26 PM
	Read Replies (1) of 52153

." FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space." Does anyone here maintain an interest in FGEN? I just reread this PR piece which says they are spending $35mm to expand their R&D portfolio. Should I assume they are striking out on Pamrevlumab or that a few scientists just can't be retained without following a new hot interest? Or am I too suspicious and they simply see a wonderful opportunity which, even though the company is not profitable, they simply can't afford to pass up? Or finally, that this expense is warranted by it's ability to improve/expand the promise of Roxadustat and Pamrevlumab?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next